Market News & Trends
Mayne Pharma Receives FDA Approval; Acquires Portfolio From Teva & Allergan
Mayne Pharma Inc. has received approval from the US FDA to market dofetilide capsules, a generic alternative to Tikosyn, an anti-arrhythmic agent used to treat…
MilliporeSigma Expands Excipients Portfolio, Adding Polymers for Sustained Release Injectables
Allows for more precise control of release kinetics Enables development of drugs requiring fewer injections for enhanced patient comfort and compliance Billerica, Massachusetts, July 12,…
Mayne Pharma Receives FDA Approval; Acquires Portfolio From Teva & Allergan
Mayne Pharma Inc. has received approval from the US FDA to market dofetilide capsules, a generic alternative to Tikosyn, an anti-arrhythmic agent used to treat…
MilliporeSigma Expands Excipients Portfolio, Adding Polymers for Sustained Release Injectables
Allows for more precise control of release kinetics Enables development of drugs requiring fewer injections for enhanced patient comfort and compliance Billerica, Massachusetts, July 12,…
Tesaro Raises $377 Million
TESARO, Inc. recently announced it has commenced an underwritten public offering of $300 million of its common stock. In connection with this offering, TESARO plans…
Merck Provides Results of Pivotal Study That Confirms Addition of Erbitux to FOLFOX Significantly Improves Outcomes
Merck presented data at the ESMO 18th World Congress on Gastrointestinal Cancer (WCGC) from the pivotal Phase III TAILOR study in patients from China, the…
Aeterna Zentaris & Orient Europharma Sign License Agreement
Aeterna Zentaris Inc. and Orient EuroPharma Co., Ltd. recently announced the signing of an exclusive license agreement between the company and Cyntec Co., Ltd., an…
RiboMed Biotechnologies & Tocagen Collaborate to Analyze Epigenetic Prognostic Markers, Including MGMT, in Recurrent Brain Tumors
RiboMed Biotechnologies, Inc. and Tocagen Inc. recently announced a collaboration to analyze potential epigenetic prognostic and predictive markers, including the gene for the DNA repair…
Relmada Therapeutics Secures First European Patent Covering LevoCap ER
Relmada Therapeutics, Inc. recently announced it has been granted a patent from the European Patent Office (EPO) for compositions and methods of use for its…
Global Urological Cancers Market Will Double to $35.9 billion by 2022
The urological cancers market, including bladder, kidney, prostate, and testicular cancer, will increase from $17.9 billion in 2015 to $35.9 billion by 2022, at a…
West’s SmartDose(®) Drug Delivery Technology Platform Selected by Amgen for Pushtronex™ System
On-body Infusor with Prefilled Cartridge to Deliver Monthly Single Dose of Repatha® (evolocumab) West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in…
Everon Biosciences Introduces New Age-Related Cellular Target That Changes Focus of Anti-Aging Drug Discovery
A research team from Everon Biosciences, Inc. and Roswell Park Cancer Institute has identified a specific subpopulation of immune cells accumulating in old mice that…
BeiGene Announces Initiation of a Combination Trial of the BTK Inhibitor BGB-3111 With the PD-1 Antibody BGB-A317
BeiGene, Ltd. recently announced the dosing of the first patient in a Phase I clinical trial of BGB-3111, a Bruton’s tyrosine kinase (BTK) inhibitor, in…
Biogen & AbbVie’s Once-Monthly ZINBRYTA Approved in European Union
The European Commission (EC) has granted marketing authorization for ZINBRYTA (daclizumab) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), Biogen…
Intrexon & ZIOPHARM Amend Exclusive Channel Collaborations
Intrexon Corporation and ZIOPHARM Oncology, Inc. recently announced amendments to their Exclusive Channel Collaborations (ECCs) in the fields of oncology and graft-versus-host-disease (GvHD) to improve…
Intra-Cellular Therapies Reports Completion of Enrollment of Phase III Clinical Trial
Intra-Cellular Therapies, Inc. recently announced completion of enrollment in the second Phase III clinical trial (ITI-007-302) of the company's lead product candidate ITI-007 for the…
ICON to Acquire Clinical Research Management
ICON plc, a global provider of drug development solutions and services to the pharmaceutical, biotechnology, and medical device industries, recently announced it has agreed, subject…
Owen Mumford Unveils New Self-Injection Pen
Owen Mumford, a global industry leader in medical device design and manufacturing, recently unveiled a new addition to its range of medical devices, Ovaleap Pen.…
Ligand Receives $4 Million From Expansion of Two OmniAb License Agreements
Ligand Pharmaceuticals Incorporated recently announced that two recent events relating to its OmniAb platform generated $4 million in combined payments due to Ligand. One event…
Cytokinetics Announces Start of Phase II Clinical Trial
Cytokinetics, Inc. recently announced the start of a randomized, double-blind, placebo-controlled, two-period crossover clinical trial designed to assess the effect of CK-2127107 (CK-107) on physical…
